UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 18, 2018
GTx, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 000-50549 | | 62-1715807 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File
Number) | | (IRS Employer Identification No.) |
175 Toyota Plaza
7th Floor
Memphis, Tennessee | | 38103 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (901) 523-9700
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events.
On May 18, 2018, GTx, Inc. issued a press release announcing the release of additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
99.1 | | Press Release issued by GTx, Inc. dated May 18, 2018 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 18, 2018 | GTx, Inc. |
| |
| By: | /s/ Henry P. Doggrell |
| Name: | Henry P. Doggrell |
| Title: | Vice President, Chief Legal Officer and Secretary |
4
